InvestorsObserver
×
News Home

Adma Biologics Up 7.72% To $3.33 After Earnings Meet

Friday, March 24, 2023 11:07 AM | InvestorsObserver Analysts

Mentioned in this article

Adma Biologics Up 7.72% To $3.33 After Earnings Meet

ADMA Biologics Inc (ADMA) missed earnings projections on 3/23/2023 for Q4 2022.

Analyst expectations for Adma Biologics earnings per share (EPS) were at a loss of $0.06 per share, with the company missing those estimates with a reported EPS loss of $0.06 per share, leading to a neutral surprise of $0 per share. Adma Biologics's earnings rose 33% year-over-year as the firm reported an EPS loss of $0.09 per share in its year-ago quarter. The positive annual growth shows the Healthcare company is performing well amid recent economic conditions.

Revenues were upbeat at $50 million. That is an increase of 89.44% in revenues from the year-ago report and is 8.82% higher than consensus estimates set at $45.9 million.

The stock is up 7.72% to $3.33 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Adma Biologics a Bullish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 76. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App